Novel MVA Virus and Uses Thereof
AssigneeProbiogen AG
InventorsIngo Jordan, Volker Sandig
Life of this patent
Estimating the term…
Abstract
The present invention relates to a novel Modified Vaccinia Ankara (MVA) virus. The present invention also relates to a method for culturing said MVA virus and to a method for producing said MVA virus. Further, the present invention relates to a pharmaceutical composition comprising said MVA virus and one or more pharmaceutical acceptable excipient(s), diluent(s), and/or carrier(s). Furthermore, the present invention relates to a vaccine comprising said MVA virus. In addition, the present invention relates to said MVA virus for use in medicine.
Claims21
A Modified Vaccinia Ankara (MVA) virus comprising a nucleic acid sequence encoding an A3L gene product and/or an A34R gene product, wherein said nucleic acid sequence comprises at least one mutation resulting in an amino acid sequence modification of said gene product(s).
(canceled)
(canceled)
-40. (canceled)
Dependencies are inferred from the claim text.